IMMUNO-BIOLOGICAL LABORATORIES CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 503 JPY | +1.21% |
|
+6.34% | +2.03% |
Valuation
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 11,530 | 6,020 | 5,001 | 5,141 | 3,046 | 3,791 |
| Enterprise Value (EV) 1 | 10,138 | 5,148 | 4,254 | 4,627 | 2,771 | 3,411 |
| P/E ratio | -211 x | -36.1 x | -7.07 x | -16.2 x | -11.8 x | -13.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 15.2 x | 7.71 x | 8.68 x | 8.54 x | 4.71 x | 4.77 x |
| EV / Revenue | 13.4 x | 6.59 x | 7.39 x | 7.69 x | 4.28 x | 4.3 x |
| EV / EBITDA | 35.1 x | - | - | - | - | - |
| EV / FCF | 97.7 x | -28.6 x | -10.7 x | -32.7 x | -14.4 x | 28.5 x |
| FCF Yield | 1.02% | -3.49% | -9.34% | -3.06% | -6.94% | 3.51% |
| Price to Book | 6.03 x | 2.91 x | 2.57 x | 3.16 x | 2.23 x | 3.52 x |
| Nbr of stocks (in thousands) | 7,897 | 8,419 | 9,313 | 9,313 | 9,313 | 9,313 |
| Reference price 2 | 1,460 | 715.0 | 537.0 | 552.0 | 327.0 | 407.0 |
| Announcement Date | 6/29/18 | 6/28/19 | 6/29/20 | 6/30/21 | 6/30/22 | 6/30/23 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 758 | 781 | 576 | 602 | 647 | 794 |
| EBITDA 1 | 289 | - | - | - | - | - |
| EBIT 1 | -49 | -173 | -596 | -241 | -122 | 52 |
| Operating Margin | -6.46% | -22.15% | -103.47% | -40.03% | -18.86% | 6.55% |
| Earnings before Tax (EBT) 1 | -52 | -164 | -659 | -310 | -250 | -280 |
| Net income 1 | -52 | -167 | -668 | -318 | -258 | -289 |
| Net margin | -6.86% | -21.38% | -115.97% | -52.82% | -39.88% | -36.4% |
| EPS 2 | -6.927 | -19.79 | -75.99 | -34.14 | -27.70 | -31.03 |
| Free Cash Flow 1 | 103.8 | -179.8 | -397.5 | -141.6 | -192.2 | 119.9 |
| FCF margin | 13.69% | -23.02% | -69.01% | -23.53% | -29.71% | 15.1% |
| FCF Conversion (EBITDA) | 35.9% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 6/29/18 | 6/28/19 | 6/29/20 | 6/30/21 | 6/30/22 | 6/30/23 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: |
|---|
Estimates
Balance Sheet Analysis
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1,392 | 872 | 747 | 514 | 275 | 380 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 104 | -180 | -398 | -142 | -192 | 120 |
| ROE (net income / shareholders' equity) | -3.1% | -8.02% | -32.6% | -17.8% | -17.2% | -23.6% |
| ROA (Net income/ Total Assets) | -0.91% | -3.44% | -13.9% | -7.16% | -4.3% | 2.07% |
| Assets 1 | 5,706 | 4,852 | 4,806 | 4,444 | 5,994 | -13,957 |
| Book Value Per Share 2 | 242.0 | 246.0 | 209.0 | 175.0 | 147.0 | 116.0 |
| Cash Flow per Share 2 | 301.0 | 177.0 | 111.0 | 64.90 | 54.50 | 65.90 |
| Capex | - | - | - | 13 | - | - |
| Capex / Sales | - | - | - | 2.16% | - | - |
| Announcement Date | 6/29/18 | 6/28/19 | 6/29/20 | 6/30/21 | 6/30/22 | 6/30/23 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.03% | 29.81M | |
| +31.89% | 694B | |
| +29.31% | 593B | |
| -1.71% | 371B | |
| +19.62% | 331B | |
| +6.74% | 290B | |
| +14.26% | 239B | |
| -3.15% | 209B | |
| +10.03% | 209B | |
| +8.21% | 169B |
- Stock Market
- Equities
- 4570 Stock
- Financials Immuno-Biological Laboratories Co., Ltd.
